KPL
Sinovac Biotech Ltd. welcomed over 30 foreign media representatives from Asia-Pacific and Arabic regions to its headquarters for an "Open Day for International Media."
(KPL) Sinovac Biotech Ltd. welcomed over 30 foreign media representatives from Asia-Pacific and Arabic regions to its headquarters for an "Open Day for International Media."
The event showcased the company’s contributions to global health, including an inside tour and presentations on its vaccine development efforts.
Deputy General Manager Ying Zhang of Sinovac Life Sciences Co., Ltd. outlined the company’s founding history, core products, and future research plans.
Sinovac, guided by its motto "Supply vaccines to eliminate human diseases," has developed eight critical vaccines, including CoronaVac (COVID-19 vaccine), hepatitis A and B vaccines (Healive), varicella vaccine, and poliomyelitis vaccine.
Global Impact of CoronaVac
Approved in over 60 countries and regions, CoronaVac has delivered more than 2.9 billion doses worldwide. It was among the first COVID-19 vaccines authorized by the WHO for emergency use in children as young as three years old, with pediatric approvals in over a dozen countries.
During the pandemic, Sinovac supported global efforts by supplying millions of doses, including to Laos through Chinese government partnerships.
The event highlighted Sinovac’s commitment to saving lives and advancing public health through vaccine innovation.
KPL
